Verrica Pharmaceuticals Inc. (VRCA)

NASDAQ: VRCA · USD

$3.50

+0.03 (+0.9%)· Recorded snapshot

Market cap	60.1M
Revenue (ttm)	30.3M
Net income (ttm)	-31.2M
EPS (ttm)	-$1.88
Shares out	17.2M
Volume	19,971
Beta	1.61

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 30.3M
Net income (ttm): -31.2M
EPS (ttm): -$1.88
Market cap: 60.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-120

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VRCA indicators

Market & fundamental data

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001660334
Company name	Verrica Pharmaceuticals Inc.
Country	United States
Country code	US
CUSIP number	92511W207
Earnings date	2026-11-13
Earnings time	bmo
Employees	76
Employees change	5
Employees growth	7.04%
Enterprise value	$50.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2013
Industry	Biotechnology
IPO date	2018-06-15
Is primary listing	Yes
Is SPAC	No
ISIN number	US92511W2070
Last 10-K release date	2026-03-11
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2025-07-25
Last stock split type	Reverse
Market cap	$60.1M
Market cap category	Micro-Cap
Next earnings date	2026-11-13
Options	Yes
Price	$3.50
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	VRCA
U.S. state	Pennsylvania
Website	https://www.verrica.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-53.79%
EV/Sales	1.66x
FCF / EV yield	-26.58%
FCF yield	-22.39%
Forward EV/Sales	1.67x
Forward P/S	1.98x
P/B ratio	13.84x
P/S ratio	1.97x
Price / tangible book value	13.84x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-87.18%
EBITDA margin	-85.63%
Gross margin	37.68%
Operating margin	-87.18%
Pretax margin	-102.84%
Profit margin	-102.84%
Profit per employee	$-410,303
Revenue per employee	$398,961
ROA	-43.98%
ROA (5Y)	-36.86%
ROCE	-194.72%
ROE (5Y)	-437.08%
ROIC	-120.04%
SBC / revenue	11.59%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Gross profit growth	128.04%
Gross profit growth 5Y	-0.98%
Net income growth years	1
Revenue growth	106.21%
Revenue growth (Q)	-53.85%
Revenue growth (QoQ)	16.7%
Revenue growth 3Y	52.16%
Revenue growth 5Y	20.37%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$469,000
EBIT	$-26.4M
EBITDA	$-26M
EPS	$-1.88
FCF per share	$-0.78
Financing cash flow	$9.4M
Free cash flow	$-13.3M
Free cash flow minus SBC	$-16.9M
Gross profit	$11.4M
Net borrowing	$-40.2M
Net cash flow	$-3.9M
Net income	$-31.2M
Operating cash flow minus SBC	$-16.9M
Operating income	$-26.4M
Revenue	$30.3M
Stock-based compensation	$3.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-13.16
Book value per share	$0.25
Debt / equity	0.42
Interest coverage	-7.08
Long-term assets	$3.4M
Long-term liabilities	$9.3M
Net cash (debt)	$9.4M
Net cash / market cap	15.75%
Net debt / equity	-2.18
Piotroski F-Score	4
Property, plant and equipment	$2M
Shareholders' equity	$4.3M
Tangible book value	$4.3M
Tangible book value per share	$0.25
Total assets	$36M
Total cash	$11.2M
Total debt	$1.8M
Total liabilities	$31.7M
WACC	17.5%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.81
Current assets	$32.6M
Current liabilities	$22.4M
Current ratio	1.45
Inventory turnover	7.22
Net working capital	$-45,000
Quick ratio	0.99
Working capital	$10.2M
Working capital turnover	3.42

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-117.95%
Dividend yield	0%
Shareholder yield	-117.95%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$5.44
1D price change	0.86%
1M price change	-19.91%
1M total return	-19.91%
1W price change	0.86%
1W total return	0.86%
1Y price change	-6.91%
1Y return CAGR	-6.92%
1Y total return	-6.91%
20-day SMA	$3.85
200-day SMA	$5.65
3M price change	-34.58%
3M total return	-34.58%
3Y price change	-89.61%
3Y return CAGR	-52.99%
3Y total return	-89.61%
50-day SMA	$4.47
50-day SMA vs 200-day SMA	50under200
52-week high	$9.82
52-week high date	2025-11-28
52-week low	$3.28
52-week low date	2025-11-04
5Y price change	-97.27%
5Y return CAGR	-51.35%
5Y total return	-97.27%
6M price change	-48.72%
6M total return	-48.72%
All-time high	$232.90
All-time high date	2018-06-20
All-time low	$3.28
All-time low date	2025-11-04
Average true range (ATR)	$0.33
Average volume	54.7K
Beta (1Y)	4.86
Beta (2Y)	1.74
Beta (5Y)	1.61
Change from 52-week high	-64.36%
Change from 52-week low	6.71%
Change from all-time high	-98.5%
Change from all-time low	6.71%
Change from open	2.34%
Day's gap	-1.44%
Dollar volume	$69,899
High price	$3.50
Low price	$3.40
Monthly RSI	35.84
Open price	$3.42
Position in 52-week range	100%
Previous close	$3.47
Price vs 150-day SMA	-35.67%
Price vs 20-day SMA	-9.02%
Price vs 200-day SMA	-38.09%
Price vs 50-day SMA	-21.67%
Relative volume	0.37
RSI	37.26
Sharpe ratio	0.33
Sharpe ratio (3Y)	-0.25
Sharpe ratio (5Y)	-0.23
Sortino ratio	0.64
Sortino ratio (3Y)	-0.32
Sortino ratio (5Y)	-0.28
Volume	20K
Weekly RSI	35.65
YTD price change	-57.88%
YTD total return	-57.88%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	12.4M
Float percentage	72.22%
Shares change (QoQ)	0%
Shares change (YoY)	117.95%
Shares held by insiders	2.92%
Shares held by institutions	21.93%
Shares outstanding	17.2M
Short % of float	1.58%
Short % of shares	1.14%
Short ratio	3.8 days

Deeper analysis on VRCA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VRCA report

Is a complete VRCA research report available?

No complete published report is available for Verrica Pharmaceuticals Inc. (VRCA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Verrica Pharmaceuticals Inc. (VRCA)

Price

Financial snapshot

Fair-value bridge

Latest news · VRCA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VRCA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VRCA

Frequently asked questions